多发性内分泌腺瘤病 中国就医指南

Multiple Endocrine Neoplasia (MEN) is a group of rare, inherited autosomal dominant disorders characterized by the development of tumors—often benign but sometimes malignant—in two or more endocrine glands. The three main clinical subtypes are MEN1, MEN2A, and MEN2B, each defined by distinct genetic mutations, tumor spectra, and natural histories. MEN1 is caused by inactivating mutations in the *MEN1* tumor suppressor gene on chromosome 11q13, leading to hyperplasia and neoplasia primarily in the parathyroid glands (90–95% prevalence), anterior pituitary (30–40%), and pancreaticoduodenal neuroendocrine tissues (30–80%, including gastrinomas, insulinomas, and non-functioning tumors). MEN2 syndromes arise from gain-of-function mutations in the *RET* proto-oncogene on chromosome 10q11.2; MEN2A features medullary thyroid carcinoma (MTC, nearly 100% penetrance), pheochromocytoma (50%), and primary hyperparathyroidism (20–30%), while MEN2B adds mucosal neuromas, marfanoid habitus, and aggressive MTC with early onset. Pathogenesis centers on dysregulated cell proliferation, apoptosis evasion, and hormone hypersecretion due to germline mutation-driven endocrine cell transformation. Epidemiologically, MEN1 affects approximately 1 in 30,000 individuals, with no gender predilection; MEN2 occurs in roughly 1 in 35,000–50,000. Penetrance is high (>95% for key components by age 50), and de novo mutations account for <5% of cases. Key risk factors include a confirmed pathogenic germline variant and a first-degree relative with MEN—making genetic counseling and predictive testing critical for at-risk family members. Diagnosis relies on clinical criteria, biochemical screening (e.g., serum calcium, PTH, prolactin, gastrin, calcitonin, metanephrines), imaging (MRI, CT, Ga-68 DOTATATE PET/CT), and confirmatory germline genetic testing. Untreated or suboptimally managed MEN significantly impairs quality of life: recurrent hypercalcemia causes fatigue, nephrolithiasis, and cognitive fog; hormone-secreting tumors provoke debilitating symptoms (e.g., Zollinger–Ellison syndrome diarrhea/ulcers, insulinoma-induced neuroglycopenia, pheochromocytoma-related hypertension crises); surgical interventions carry risks of hypoparathyroidism or adrenal insufficiency; and lifelong surveillance generates psychological burden, financial strain, and occupational limitations. Early diagnosis, risk-stratified prophylactic surgery (especially thyroidectomy in *RET* carriers), targeted medical therapies (e.g., everolimus for progressive pancreatic NETs, vandetanib for advanced MTC), and multidisciplinary care—including endocrinology, endocrine surgery, nuclear medicine, genetics, and oncology—are essential to mitigate morbidity, prevent metastatic disease, and preserve long-term function and well-being.

# 多发性内分泌腺瘤病（MEN）治疗方案与费用明细（内分泌科）

一、非手术/药物/保守管理方案

适用于MEN1/MEN2A早期无功能肿瘤、生化异常但影像学阴性者，或手术禁忌患者。

• •药物控制：奥曲肽LAR（30mg/月）：8,200–9,500元/支；卡博替尼（MEN2B晚期）：12,600–14,800元/盒（40mg×30粒）
• •生化监测：血钙、PTH、胃泌素、降钙素、胰岛素样生长因子-1（IGF-1）等12项联检：1,280–1,650元/次
• •影像随访：颈部超声（含弹性成像）+腹部MRI增强：2,400–3,100元/次

二、手术/微创干预方案

适用于功能性肿瘤（如甲状旁腺亢进、嗜铬细胞瘤、甲状腺髓样癌）、肿瘤≥1cm或进展性病变。

• •双侧甲状腺全切+中央区淋巴结清扫（MEN2A/B）：术前肾上腺CT+MIBG显像（2,900–3,700元），手术费+麻醉+病理+住院（7–10天）：48,000–62,000元
• •腹腔镜肾上腺切除（嗜铬细胞瘤）：术前α受体阻滞准备（酚苄明疗程）+术中血流动力学监护：42,000–55,000元

三、复杂/晚期/并发症方案

MEN1合并胰十二指肠神经内分泌癌（pNET）、肝多发转移或耐药性MTC：

• •PRRT（¹⁷⁷Lu-DOTATATE）：3周期（含SPECT/CT评估、氨基酸保护）：280,000–320,000元
• •靶向联合免疫（舒尼替尼+PD-1抑制剂）：首年治疗及毒性管理：350,000–410,000元

四、方案快速选择指南

• •预算≤5万元/年：优选药物+严密随访（MEN1无功能瘤）
• •预算8–15万元且需根治：优先行规范甲状腺/肾上腺微创切除
• •晚期转移或耐药：转诊至国家级内分泌肿瘤中心启动PRRT或临床试验（部分项目减免检测费）